Introduction
Primary hepatocellular carcinoma (HCC) is among the leading cause of cancer-related deaths in the U.S., with 40,000 new cases and 30,000 mortalities in 2018 (1) . Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, obesity, and excess alcohol consumption are risk factors associated with HCC (2) . HCC resulting from chronic viral infections constitute 75% of all cases, while the non-viral causes account for the remaining 25%. Importantly, both viral and non-viral HCC involve inflammation of the liver and progress from cirrhosis(3). Secondary liver cancers, which originate by the metastatic spread of a primary tumor from a distant site, are more frequent than HCC (4) . Although current treatment strategies including surgical resection, radiation, ablation, embolization, systemic/local chemotherapy infusion and liver transplantation have improved the outcome of patients with HCC and cholangiocarcinoma (CCA), liver cancers are diagnosed at advanced stages with poor clinical presentation and have high recurrence rates(5).
Thus, there is an urgent need to gain mechanistic insight into the pathobiology of primary and metastatic liver cancers and develop more effective therapeutic opportunities.
Tumors employ multiple mechanisms to evade immune recognition and to establish an immunosuppressive microenvironment promoting their growth. Myeloid-derived suppressor cells (MDSCs) are a heterogenous population of immature myeloid cells that expand in patients with malignancies and infiltrate tumors, where they confine anti-tumor immune response by suppressing cytotoxic T cell and natural killer (NK) cell activity (6) . Previous work demonstrated that high MDSC frequency in melanoma not only correlates with poor patient outcome but also associates with therapeutic irresponsiveness (6) (7) (8) (9) . Targeting MDSCs in multiple preclinical models including colorectal and liver cancers activated an anti-tumor immune response and reduced tumor growth, suggesting that modulating these cells is a promising strategy for cancer immunotherapy (10, 11) . Several studies have reported that MDSCs are augmented in peripheral blood of HCC patients (12) (13) (14) (15) . However, the relevance of this observation in terms of other hepatobiliary malignancies, including non-viral HCC, and patient clinical presentation has yet to be determined. Considering the range and pathobiological variation in primary and metastatic liver cancers, we hypothesized that MDSCs might have distinct associations with different types of hepatobiliary tumors. By screening peripheral blood samples and liver surgical specimens from patients with HCC, CCA, colorectal carcinoma with liver metastasis (CRLM) and neuroendocrine tumors (NET), we identified that MDSCs are elevated in most but not all liver cancers. Our findings demonstrate that MDSC augmentation is impacted by the type of liver tumors, and support testing of MDSC targeting strategies in patients with HCC, CRLM and NET.
Materials and Methods

Reagents
Fluorophore-conjugated anti-human CD3 (clone UCHT1), CD4 (clone SK3), CD8 (clone RPA-T8), CD14 (clone MφP9), CD15 (clone HI98), CD25 (clone M-A251), CD33 (clone WM53), CD107a (H4A3), CD127 (clone HIL-7R-M21) and HLA-DR (clone G46-6) antibodies were purchased from BD Biosciences. CD11b (clone CD11B29) antibody and LIVE/DEAD™ Fixable Blue Dead Cell Stain Kit, for UV excitation was obtained from ThermoFisher Scientific.
Patients
Peripheral blood samples were collected perioperatively from 100 patients with primary liver lesions or liver metastases in the Cleveland Clinic. All patients provided written informed consent under IRB 10-347 and the protocol was approved by the Cleveland Clinic Institutional Review Board. Only non-viral HCC specimens were included to the study and all the diagnoses were confirmed by the Cleveland Clinic Pathology Department. Patient information is provided in Table   1 .
Quantification of MDSC in peripheral blood
Peripheral blood samples were processed using a Ficoll-Paque PLUS gradient in a SepMateTM (Stem Cell Technologies) and frozen in 10% dimethyl sulfoxide (Fisher Scientific) and 90% fetal bovine serum (Gibco) until further analysis. Samples were stained with live/dead UV stain (Invitrogen) for 10 minutes on ice and blocked in FACS buffer (PBS, 2% BSA) containing an FcR blocking reagent at 1:50 (Miltenyi Biotec) on ice for 15 minutes. Samples were stained with fluorophore-conjugated antibody cocktails for 20 minutes on ice, washed with FACS buffer and analyzed using LSRFortessa (BD Biosciences). Analysis were performed using FlowJo software (Tree Star Inc.).
Immunohistochemistry (IHC)
Liver biopsy specimens were available in 29 patients (6 HCC, 9 benign, 10 CCA and 4 NET) for IHC analysis. Formalin fixed paraffin-embedded blocks and H&E stained slides were retrieved and reviewed in these 29 cases. Additional IHC stains were performed on a selected representative block from each case. IHC was performed using the mouse monoclonal CD33 antibody (clone PWS44, Leica Biosystems) diluted 1:100 using SignalStain Diluent (Cell Signaling 
Results
MDSCs are increased in peripheral blood of primary and metastatic liver tumor patients
MDSCs are bone marrow-derived immature immunosuppressive cells that accumulate in patients with malignancies (8, 16 (Fig 1B) . Although patients with NET and CRLM also had MDSC expansion in their circulation, CCA patients had significantly lower rates of peripheral MDSCs in comparison to HCC patients (Fig 1B) . MDSC percentages in CCA patients were indistinguishable from those with benign liver lesions (Fig 1B) . Prior studies suggest that mMDSCs are the main population in patients with liver cancers (13) (14) (15) . Consistently, our findings demonstrated that CD14 + CD15 -mMDSC subset constitute the majority of MDSCs in peripheral circulation, and that these cells are present at higher rates in patients with HCC compared to those with CCA or benign lesions (Fig 1C-D Fig 1A) . However, within the HCC group, there was a significant correlation between MDSC percentages and ALT levels (p<0.001), indicating that MDSCs could be impacted by the severity of liver damage (Supplemental Fig 1B) . Carcinoembryonic antigen (CEA) is a marker elevated in peripheral blood of patients with colorectal cancer and an indicator of liver metastases (20) . To examine whether MDSC frequency is linked to disease severity we separately investigated CEA levels in CRLM patients with high (>4.8%) versus low (<4.8%) MDSC score.
CRLM patients with more MDSCs also exhibited increased levels of CEA (p<0.01, Supplemental   Fig 1C) .
Benign liver lesions are infiltrated by antigen-presenting cells (APCs)
Under normal physiological conditions, mMDSCs are capable of differentiating in to antigenpresenting dendritic cells (DCs) and macrophages (6) . This pathway has been hypothesized to be halted under pathophysiological conditions such as cancer, leading to accumulation of these cells in host. Thus, we investigated whether enhanced MDSC frequency associated with APC infiltration of liver lesions by performing immunohistochemistry staining of pan-myeloid marker CD33, MHC Class II HLA-DR and macrophage marker CD68 in a subset of HCC, CCA, NET and benign cases. Malignant tumors exhibited a similar immune profile with no significant differences in the number of CD33, HLA-DR and CD68 positive cells in peak areas counted within the tumors (Fig 2A-B Fig 2C) , representing APCs.
CD68
+ cells corresponding to macrophages, including resident Kupffer cells, were not different between malignant and benign liver lesions (Fig 2B-C) , suggesting that DCs constitute the majority of infiltrating APCs in benign cases. In addition, we analyzed whether the immunosuppressive tumor microenvironment prevents infiltration of myeloid cells leading to the accumulation of these cells at the periphery (tumor-normal interface). Intralesional versus peripheral specimens from the matching tumors had similar numbers of CD33 or CD68 positive cells, CCA cases being the exception (Fig 2D) . These results suggest that HCC and NETs result in reduced myeloid cell accumulation in the tumor as well as the adjacent tissue.
MDSC frequency correlates with HCC outcome
Although HCC patients had significantly higher levels of MDSCs compared to patients with CCA or benign lesions, this patient subpopulation could further be clustered into MDSC high (>4.8%) versus MDSC low (<4.8%) group based on flow cytometry analysis (Fig 1B) . Based on this variation at the level of individual patient immune response, we investigated whether MDSC frequency correlates with disease outcome using the TCGA dataset containing gene expression information from 440 HCC patients. We generated a high versus low MDSC score by focusing on high CD33 and CD11b expression and further creating subgroups based on the median levels of (Fig 3B) . Similarly, activated CD8 + T cell signature did not predict survival advantage over having more naïve CD107a low T cells in the tumor microenvironment (Fig 3C) . Together, these observations suggest that MDSCs but not
Tregs or activated CD8 + T cells associate with HCC outcome. is an independent predictor of malignancy and not confounded by clinical variables. However, the majority of the patients in the entire cohort had AST and ALT levels <40 IU/ml suggesting that they had minimum liver damage (30) . Still, we identified a positive correlation between serum ALT levels and MDSC frequency in non-viral HCC patients, which implies that chronic inflammation and accompanying liver damage may be linked to MDSC augmentation. Furthermore, CEA levels were significantly higher in CRLM patients with above average MDSC percentages. Despite lack of strong association between CEA levels and tumor burden, patients with Grade III and Grade IV colon cancers have higher serum CEA concentrations (31) .
Unlike gMDSCs, which are hypothesized to be terminally differentiated, mMDSCs can polarize into DCs and macrophages. However, this maturation pathway is impaired under pathophysiological conditions (32, 33) . Since mMDSCs were the prevalent cell type in patients with liver cancer, we speculated that mMDSC-APC differentiation axis was hindered in malignant tumors leading to accumulation of the former population in tissues. Lower number of intralesional CD33 positive cells in malignant tumors pointed out to a potential reduction in myeloid infiltration.
It is also possible that the CD33 staining intensity is biasing the results, as APCs express higher levels of CD33 compared to immature myeloid cells (34) . In contrast, the decreased number of positive intralesional cells observed in HLA-DR stain in CCA and HCC with respect to the benign lesions may suggest a reduced ability to elicit an immune response in these tumors.
In line with this observation, HCC patients with high tissue APC score, which was generated based on high CD33, high CD11b and high HLA-DR expression in TCGA dataset, had survival advantage. One possible explanation of decreased CD33 and HLA-DR positive cells in malignant tumors is that ENTPD2/CD39L expression by tumor cells hinders MDSC maturation in liver tumors (35) . Although this is yet to be confirmed in HCC patients, low MDSC frequencies in CCA patients suggest that there might be alternative mechanisms impairing trafficking or maturation of APCs in this tumor type.
Collectively, our results identify a distinct immune signature presented as high circulating MDSC levels and low tumor-infiltrating APCs in non-viral HCC as opposed to low peripheral MDSCs and more intrahepatic APCs in benign lesions (Fig 4) . Our findings make the case for including blood MDSC measurement as a diagnostic test for primary and metastatic hepatobiliary malignancies. 
